AMENDMENTS TO THE CLAIMS

1. (Original) An intravitreous injectable solution for the treatment of vitreous hemorrhages, which comprises: a pharmaceutically effective quantity of an active ingredient; and a pharmaceutically acceptable quantity of a carrier solution; wherein the active ingredient is mannitol and the carrier solution comprises 10.20% in weight of polyoxyl stearate 40; 0.15% in weight of edetate disodium, dihydrate; 1.03% in weight of sodium chloride; 0.14% in weight of boric acid; 0.32% in weight of sorbic acid; 0.06% in weight of sodium bisulfate and 88.00% in weight of distilled water.

2. (Currently amended) The intravitreous injectable solution, according to claim 1, ~~characterized in that~~ wherein said carrier solution is Sophisen®.

3. (Currently amended) The intravitreous injectable solution, according to claim 1, ~~characterized in that~~ wherein mannitol is present in a concentration that encourages the reabsorption of the vitreous hemorrhage.

4. (Currently amended) The intravitreous injectable solution, according to claim 3, ~~characterized in that~~ wherein the mannitol is present in the solution in a percentage of 5% to 30% in weight.

5. (Currently amended) The intravitreous injectable solution, according to claim 1, ~~characterized in that~~ wherein the Sophisen® is present in the solution in a percentage of 0.05% to 20% in weight.

6. (Currently amended) The intravitreous injectable solution, according to claim 1, ~~characterized in that~~ wherein the pH of the solution is approximately 7.2.

7. (Currently amended) The intravitreous injectable solution, according to claim 1, ~~characterized in that~~ wherein the solution has an osmolarity of approximately 1400 mOsm/kg.

8. (Currently amended) A method for the treatment of vitreous hemorrhages comprising ~~the steps of: applying at least one injection of~~ injecting an ophthalmic solution ~~including~~ comprising mannitol[[,]] into the vitreous humor of an eye with a hemorrhage resulting from a lesion or disease.

9. (Currently amended) The method according to claim 8, ~~characterized by applying at least one therapeutically effective dose of the injectable~~ wherein the ophthalmic solution ~~of~~

~~claim 1, into the vitreous humor of a patient diagnosed with vitreous hemorrhage~~ comprises a pharmaceutically effective quantity of an active ingredient; and a pharmaceutically acceptable quantity of a carrier solution; wherein the active ingredient is mannitol and the carrier solution comprises 10.20% in weight of polyoxyl stearate 40; 0.15% in weight of edetate disodium, dihydrate; 1.03% in weight of sodium chloride; 0.14% in weight of boric acid; 0.32% in weight of sorbic acid; 0.06% in weight of sodium bisulfate and 88.00% in weight of distilled water.

10. (Currently amended) A method for the clarification of vitreous hemorrhages comprising ~~the injection,~~ injecting into the vitreous body of the eye of a patient~~, of~~ an ophthalmic solution, ~~such as the one claimed in claim 1~~ comprising mannitol.

11. (Currently amended) ~~The~~ A method of ~~the preceding claim, which is aimed at~~ avoiding vitrectomy surgery in patients with vitreous hemorrhage~~, by the application of at least one~~ comprising intraocularly ~~injection~~ injecting ~~of~~ an ophthalmic solution formulated for ~~the~~ reabsorption of the hemorrhage, the ophthalmic solution comprising mannitol.

12. (Cancelled)

13. (Original) A method for the preparation of an ophthalmic solution for an intravitreous injection for the treatment of vitreous hemorrhages, characterized by the following steps: pouring into a stainless steel recipient 800 ml of injectable water at a temperature of 40°C ± 2°C; beginning the agitation at 200 rpm ± 50 rpm and keeping it constant throughout the entire preparation process; slowly adding 200 g of mannitol; cooling the solution until it reaches a temperature of less than 35°C; adding 1.0 g of sodium phosphate monobasic monohydrate; adding 5.1 g of sodium phosphate dibasic anhydrous; adding 1.0 ml of Sophisen®; bringing it to a volume of 1 liter with injectable water; and agitating at 200 rpm ± 50 rpm until complete homogeneity is obtained.

14. (Original) An intravitreous injectable solution for the treatment of vitreous hemorrhages comprising: a pharmaceutically effective quantity of mannitol: 0.01% to 5% in weight of sodium phosphate monobasic monohydrate; 0.01% to 5% in weight of sodium phosphate dibasic anhydrous and 100 ml of injectable water.

15. (Currently amended) The intravitreous injectable solution of claim 14, ~~in which~~ wherein the mannitol is present in a percentage of 5% to 30% in weight of the solution.

16. (Currently amended) The intravitreous injectable solution of claim 14, which further ~~includes~~ comprising 0.05% to 20% in weight of a carrier solution.

17. (Original) The intravitreous injectable solution of claim 14, wherein the carrier solution is Sophisen®.